Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion.

Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

Clin Cancer Res. 2019 May 29. pii: clincanres.3468.2018. doi: 10.1158/1078-0432.CCR-18-3468. [Epub ahead of print]

PMID:
31142503
2.

Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in Caucasians.

Cohen JI, Manoli I, Dowdell KC, Krogmann TA, Tamura D, Radecki P, Bu W, Turk SP, Liepshutz K, Hornung RL, Fassihi H, Sarkany RP FRCP, Bonnycastle LL, Chines PS, Swift AJ, Myers TG, Levoska MA, DiGiovanna JJ, Collins FS, Kraemer KH, Pittaluga S, Jaffe ES.

Blood. 2019 May 7. pii: blood.2018893750. doi: 10.1182/blood.2018893750. [Epub ahead of print]

PMID:
31064750
3.

A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.

Gupta GK, Jaffe ES, Pittaluga S.

Histopathology. 2019 Apr 2. doi: 10.1111/his.13870. [Epub ahead of print]

PMID:
30938862
4.

Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.

Karanovic D, Michelow IC, Hayward AR, DeRavin SS, Delmonte OM, Grigg ME, Dobbs AK, Niemela JE, Stoddard J, Alhinai Z, Rybak N, Hernandez N, Pittaluga S, Rosenzweig SD, Uzel G, Notarangelo LD.

Front Immunol. 2019 Feb 14;10:77. doi: 10.3389/fimmu.2019.00077. eCollection 2019.

5.

Viral, immunologic, and clinical features of primary effusion lymphoma.

Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Gonçalves PH, Ramaswami R, Marshall VA, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, Uldrick TS.

Blood. 2019 Apr 18;133(16):1753-1761. doi: 10.1182/blood-2019-01-893339. Epub 2019 Feb 19.

6.

Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liver.

Lerner AM, Bennett JE, Pittaluga S, Khil PP, Youn JH, Fahle GA, Frank KM, Dekker JP, Jerussi TD, Sun C, Wiestner A, Gea-Banacloche J.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):180-182. doi: 10.1016/j.diagmicrobio.2018.12.012. Epub 2019 Jan 2.

PMID:
30679057
7.

Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.

Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, Jaffe ES, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2019 Jan 10:1-5. doi: 10.1080/10428194.2018.1562184. [Epub ahead of print]

PMID:
30626252
8.

Plerixafor for the Treatment of WHIM Syndrome.

McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM.

N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575.

PMID:
30625055
9.

Lymphoid hyperplasia with atypical dendritic/Langerhans cell proliferation mimicking Hodgkin lymphoma.

Balakrishna JP, Raffeld M, Jaffe ES, Pittaluga S.

Histopathology. 2019 Apr;74(5):797-799. doi: 10.1111/his.13795. Epub 2019 Feb 13. No abstract available.

PMID:
30565719
10.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868
11.

Diagnosis of Hodgkin lymphoma in the modern era.

Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES.

Br J Haematol. 2019 Jan;184(1):45-59. doi: 10.1111/bjh.15614. Epub 2018 Nov 8. Review.

PMID:
30407610
12.

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2018 Oct 2;9(77):34641. doi: 10.18632/oncotarget.26214. eCollection 2018 Oct 2.

13.

Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunity.

Preite S, Cannons JL, Radtke AJ, Vujkovic-Cvijin I, Gomez-Rodriguez J, Volpi S, Huang B, Cheng J, Collins N, Reilley J, Handon R, Dobbs K, Huq L, Raman I, Zhu C, Li QZ, Li MO, Pittaluga S, Uzel G, Notarangelo LD, Belkaid Y, Germain RN, Schwartzberg PL.

Nat Immunol. 2018 Sep;19(9):986-1000. doi: 10.1038/s41590-018-0182-3. Epub 2018 Aug 20.

14.

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.

Aue G, Sun C, Liu D, Park JH, Pittaluga S, Tian X, Lee E, Soto S, Valdez J, Maric I, Stetler-Stevenson M, Yuan C, Nakamura Y, Muranski P, Wiestner A.

J Immunol. 2018 Oct 1;201(7):1967-1974. doi: 10.4049/jimmunol.1800570. Epub 2018 Aug 13.

PMID:
30104242
15.

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Taneja A, Jones J, Pittaluga S, Maric I, Farooqui M, Ahn IE, Wiestner A, Sun C.

Leuk Lymphoma. 2019 Feb;60(2):519-522. doi: 10.1080/10428194.2018.1480775. Epub 2018 Jul 6. No abstract available.

PMID:
29978754
16.

Human Herpes Virus 6 (HHV-6)-associated Lymphadenitis: Pitfalls in Diagnosis in Benign and Malignant Settings.

Balakrishna JP, Bhavsar T, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S.

Am J Surg Pathol. 2018 Oct;42(10):1402-1408. doi: 10.1097/PAS.0000000000001121.

PMID:
29975251
17.

Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.

Gong S, Crane GM, McCall CM, Xiao W, Ganapathi KA, Cuka N, Davies-Hill T, Xi L, Raffeld M, Pittaluga S, Duffield AS, Jaffe ES.

Am J Surg Pathol. 2018 Oct;42(10):1306-1316. doi: 10.1097/PAS.0000000000001113.

PMID:
29957733
18.

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM.

Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20.

19.

Aspergillosis, eosinophilic esophagitis, and allergic rhinitis in signal transducer and activator of transcription 3 haploinsufficiency.

Natarajan M, Hsu AP, Weinreich MA, Zhang Y, Niemela JE, Butman JA, Pittaluga S, Sugui J, Collar AL, Lim JK, Zangeneh T, Carr T, Oler AJ, Similuk M, Rosen LB, Desai JV, Freeman AF, Holland SM, Kwon-Chung KJ, Milner JD, Lionakis MS.

J Allergy Clin Immunol. 2018 Sep;142(3):993-997.e3. doi: 10.1016/j.jaci.2018.05.009. Epub 2018 May 24. No abstract available.

PMID:
29803798
20.

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.

Melani C, Advani R, Roschewski M, Walters KM, Chen CC, Baratto L, Ahlman MA, Miljkovic MD, Steinberg SM, Lam J, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH.

Haematologica. 2018 Aug;103(8):1337-1344. doi: 10.3324/haematol.2018.192492. Epub 2018 May 10.

21.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

22.

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A.

Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.

23.

Liver disturbances in activated phosphoinositide 3-kinase δ syndrome.

Ben-Yakov G, Kapuria D, Marko J, Cho MH, Pittaluga S, Kleiner DE, Koh C, Holland S, Uzel G, Heller T.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1763-1765. doi: 10.1016/j.jaip.2018.01.005. Epub 2018 Feb 16. No abstract available.

PMID:
29378322
24.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.

Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.

25.

STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells.

Majri SS, Fritz JM, Villarino AV, Zheng L, Kanellopoulou C, Chaigne-Delalande B, Grönholm J, Niemela JE, Afzali B, Biancalana M, Pittaluga S, Sun A, Cohen JL, Holland SM, O'Shea JJ, Uzel G, Lenardo MJ.

J Immunol. 2018 Jan 1;200(1):110-118. doi: 10.4049/jimmunol.1701133. Epub 2017 Nov 29.

26.

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2017 Aug 4;8(43):73387-73406. doi: 10.18632/oncotarget.19945. eCollection 2017 Sep 26. Erratum in: Oncotarget. 2018 Oct 2;9(77):34641.

27.

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg SM, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2018 Jun;59(6):1466-1469. doi: 10.1080/10428194.2017.1387908. Epub 2017 Oct 16. No abstract available.

28.

Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI.

Absinta M, Ha SK, Nair G, Sati P, Luciano NJ, Palisoc M, Louveau A, Zaghloul KA, Pittaluga S, Kipnis J, Reich DS.

Elife. 2017 Oct 3;6. pii: e29738. doi: 10.7554/eLife.29738.

29.

Re-evaluating TTF-1 immunohistochemistry in diffuse gliomas: Expression is clone-dependent and associated with tumor location.

Pratt D, Afsar N, Allgauer M, Fetsch P, Palisoc M, Pittaluga S, Quezado M.

Clin Neuropathol. 2017 Nov/Dec;36(6):263-271. doi: 10.5414/NP301047.

PMID:
28933335
30.

The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Facchetti F, Pileri S, Rosenwald A, Wotherspoon A, Fend F.

Virchows Arch. 2017 Oct;471(4):453-466. doi: 10.1007/s00428-017-2199-7. Epub 2017 Aug 26. Review.

PMID:
28844114
31.

Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, Gilbert MR, Quezado M.

J Neuropathol Exp Neurol. 2017 Aug 1;76(8):697-708. doi: 10.1093/jnen/nlx051.

32.

Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Facchetti F, Pileri SA, Lorenzi L, Tabanelli V, Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Rosenwald A, Wotherspoon A, Fend F.

Virchows Arch. 2017 Oct;471(4):467-489. doi: 10.1007/s00428-017-2176-1. Epub 2017 Jul 10.

PMID:
28695297
33.

PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.

Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M.

N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767. No abstract available.

34.

CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis.

Ozen A, Comrie WA, Ardy RC, Domínguez Conde C, Dalgic B, Beser ÖF, Morawski AR, Karakoc-Aydiner E, Tutar E, Baris S, Ozcay F, Serwas NK, Zhang Y, Matthews HF, Pittaluga S, Folio LR, Unlusoy Aksu A, McElwee JJ, Krolo A, Kiykim A, Baris Z, Gulsan M, Ogulur I, Snapper SB, Houwen RHJ, Leavis HL, Ertem D, Kain R, Sari S, Erkan T, Su HC, Boztug K, Lenardo MJ.

N Engl J Med. 2017 Jul 6;377(1):52-61. doi: 10.1056/NEJMoa1615887. Epub 2017 Jun 28.

35.

MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.

Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg SM, Dunleavy K, Pack S, Jaffe ES, Wilson WH.

Leuk Lymphoma. 2018 Feb;59(2):505-508. doi: 10.1080/10428194.2017.1339882. Epub 2017 Jun 22. No abstract available.

36.

B-cell lymphomas with discordance between pathological features and clinical behavior.

de Leval L, Copie-Bergman C, Rosenwald A, Rimsza L, Pittaluga S, Bisig B, Dirnhofer S, Facchetti F, Pileri S, Fend F, Wotherspoon A.

Virchows Arch. 2017 Oct;471(4):439-451. doi: 10.1007/s00428-017-2152-9. Epub 2017 Jun 1.

PMID:
28573510
37.

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH.

Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25.

38.

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29.

39.

DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation.

Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland SM, Wilson W, Dunleavy K, Shah NN, Freeman AF.

Front Pediatr. 2017 Feb 28;5:38. doi: 10.3389/fped.2017.00038. eCollection 2017.

40.

KSHV-associated and EBV-associated Germinotropic Lymphoproliferative Disorder: New Findings and Review of the Literature.

Bhavsar T, Lee JC, Perner Y, Raffeld M, Xi L, Pittaluga S, Jaffe ES.

Am J Surg Pathol. 2017 Jun;41(6):795-800. doi: 10.1097/PAS.0000000000000823. Review.

41.

Fibrin-associated EBV-positive Large B-Cell Lymphoma: An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation.

Boyer DF, McKelvie PA, de Leval L, Edlefsen KL, Ko YH, Aberman ZA, Kovach AE, Masih A, Nishino HT, Weiss LM, Meeker AK, Nardi V, Palisoc M, Shao L, Pittaluga S, Ferry JA, Harris NL, Sohani AR.

Am J Surg Pathol. 2017 Mar;41(3):299-312. doi: 10.1097/PAS.0000000000000775.

PMID:
28195879
42.

Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers.

Hong SG, Yada RC, Choi K, Carpentier A, Liang TJ, Merling RK, Sweeney CL, Malech HL, Jung M, Corat MAF, AlJanahi AA, Lin Y, Liu H, Tunc I, Wang X, Palisoc M, Pittaluga S, Boehm M, Winkler T, Zou J, Dunbar CE.

Mol Ther. 2017 Jan 4;25(1):44-53. doi: 10.1016/j.ymthe.2016.10.007. Epub 2017 Jan 4.

43.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS.

Cancer Discov. 2017 Apr;7(4):369-379. doi: 10.1158/2159-8290.CD-16-0330. Epub 2017 Jan 25.

44.

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A.

Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.

45.

Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea.

Ma CA, Xi L, Cauff B, DeZure A, Freeman AF, Hambleton S, Kleiner G, Leahy TR, O'Sullivan M, Makiya M, O'Regan G, Pittaluga S, Niemela J, Stoddard J, Rosenzweig SD, Raffeld M, Klion AD, Milner JD.

Blood. 2017 Feb 2;129(5):650-653. doi: 10.1182/blood-2016-09-737817. Epub 2016 Dec 12. No abstract available.

46.

Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation.

Xie Y, Pittaluga S, Price S, Raffeld M, Hahn J, Jaffe ES, Rao VK, Maric I.

Haematologica. 2017 Feb;102(2):364-372. doi: 10.3324/haematol.2015.138081. Epub 2016 Oct 20.

47.

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, Forman SJ, Xiao W, Guha R, Zhang X, Ferrer M, Chaperot L, Plumas J, Jaffe ES, Thomas CJ, Reizis B, Staudt LM.

Cancer Cell. 2016 Nov 14;30(5):764-778. doi: 10.1016/j.ccell.2016.10.002.

48.

Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas.

Nicolae A, Xi L, Pham TH, Pham TA, Navarro W, Meeker HG, Pittaluga S, Jaffe ES, Raffeld M.

Leukemia. 2016 Nov;30(11):2245-2247. doi: 10.1038/leu.2016.178. Epub 2016 Jun 22. No abstract available.

49.

Extrapulmonary Aspergillus infection in patients with CARD9 deficiency.

Rieber N, Gazendam RP, Freeman AF, Hsu AP, Collar AL, Sugui JA, Drummond RA, Rongkavilit C, Hoffman K, Henderson C, Clark L, Mezger M, Swamydas M, Engeholm M, Schüle R, Neumayer B, Ebel F, Mikelis CM, Pittaluga S, Prasad VK, Singh A, Milner JD, Williams KW, Lim JK, Kwon-Chung KJ, Holland SM, Hartl D, Kuijpers TW, Lionakis MS.

JCI Insight. 2016 Oct 20;1(17):e89890. doi: 10.1172/jci.insight.89890.

50.

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).

Gill AL, Green SA, Abdullah S, Le Saout C, Pittaluga S, Chen H, Turnier R, Lifson J, Godin S, Qin J, Sneller MC, Cuillerot JM, Sabzevari H, Lane HC, Catalfamo M.

AIDS. 2016 Oct 23;30(16):2487-2493.

Supplemental Content

Loading ...
Support Center